Product Recalls, New Appointments, Awareness Campaigns, and Stock Price Movements - Research Report on Abbott, AbbVie, Viropharma, Valeant Pharmaceuticals, and Salix Pharmaceuticals

Mon Dec 2, 2013 8:00am EST

* Reuters is not responsible for the content in this press release.

Product Recalls, New Appointments, Awareness Campaigns, and Stock Price Movements - Research Report on Abbott, AbbVie, Viropharma, Valeant Pharmaceuticals, and Salix Pharmaceuticals

PR Newswire

NEW YORK, December 2, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Abbott Laboratories (NYSE: ABT), AbbVie Inc. (NYSE: ABBV), Viropharma Inc. (NASDAQ: VPHM), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Abbott Laboratories Research Report

On November 27, 2013, Abbott Laboratories (Abbott) announced that the Company is initiating a voluntary recall of 20 lots of FreeStyle and FreeStyle Lite Blood Glucose Test Strips in the US. Abbott stated that it is conducting the recall as the use of these lots of test strips may produce erroneously low blood glucose results when used with "FreeStyle Blood Glucose Meter" and "FreeStyle Flash Blood Glucose Meter" (neither of which have been in production since 2010), and OmniPod Insulin Management System. The Company informed that the blood glucose test results are not affected when the test strips are used with the newer FreeStyle brand members including FreeStyle Freedom Blood Glucose Meter, FreeStyle Lite Blood Glucose Meter, and FreeStyle Freedom Lite Blood Glucose Meter. Abbott added that testing with the FreeStyle InsuLinx Blood Glucose Meter is not affected by Abbott's recall, as it uses FreeStyle InsuLinx test strips. The Company also stated that affected test strips are from lots with expiration dates between May 2014 and March 2015. Abbott added that it is notifying healthcare professionals, pharmacies, distributors and customers about the recall, instructing them to call Abbott's diabetes care customer for a replacement of the affected test strips at no charge. The Full Research Report on Abbott Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/05c1_ABT

AbbVie Inc. Research Report

On November 26, 2013, AbbVie Inc. (AbbVie) announced the launch of an international awareness campaign, See Us: Women Take a Stand on HIV, in advance of World AIDS Day on December 1, 2013. The Company stated that the campaign which focuses on the unique challenges faced by women affected by HIV,  is being launched in collaboration with an expert steering committee, including representation from women living with and affected by HIV, the medical community, the International Association of Providers in AIDS Care (IAPAC), and NAM/aidsmap, the HIV information charity. Marisol Martinez-Tristani, MD, Medical Director, Global Medical Affairs, AbbVie  said, "As a global leader in HIV, AbbVie has a long-standing commitment to providing support to people living with HIV through global initiatives that seek to increase knowledge and understanding of the effects of HIV on people living with the disease. Through this campaign we will engage in efforts to reach the HIV community to collectively improve both emotional support and long-term care for these women." The Full Research Report on AbbVie Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/273c_ABBV

Viropharma Inc. Research Report

On November 27, 2013, Viropharma Inc.'s (Viropharma) stock rose 0.02%, ending the day at $49.50. Over the previous three trading sessions, shares of Viropharma gained 0.02% compared to the Nasdaq Composite which gained 1.33% during the same period. The Full Research Report on Viropharma Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/c730_VPHM

Valeant Pharmaceuticals International Inc. Research Report

On November 25, 2013, Valeant Pharmaceuticals International Inc. (Valeant Pharmaceuticals) announced that Dr. Ari Kellen has been named as Executive Vice President/Company Group Chairman as part of Valeant's Executive Management Team, and will assume his role with effect from January 1, 2014. Valeant stated that prior to joining the Company, Dr. Ari Kellen served as a Senior Partner in McKinsey & Company's Mid-Atlantic Office. Commenting on the appointment, J. Michael Pearson, Chairman and CEO, said, "Ari's broad experience in developing comprehensive growth strategies for health care companies will be invaluable to us as we continue to expand our successful growth trends. After having worked with Ari for many years, I know that not only will he fit in well with the rest of the team, but he will be a strong advocate for the long-term shareholder focused culture at Valeant." The Full Research Report on Valeant Pharmaceuticals International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9fdd_VRX

Salix Pharmaceuticals, Ltd. Research Report

On November 27, 2013, Salix Pharmaceuticals, Ltd.'s (Salix Pharmaceuticals) stock rose 0.26%, ending the day at $85.16. Over the previous three trading sessions, shares of Salix Pharmaceuticals gained 0.69% compared to the Nasdaq Composite which gained 1.33% during the same period. The Full Research Report on Salix Pharmaceuticals, Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/04fa_SLXP

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.